Abstract

Stimulator of interferon genes (STING) contributes to immune responses against tumors and may control viral infection including SARS-CoV-2 infection. However, activation of the STING pathway by airway silica or smoke exposure leads to cell death, self-dsDNA release, and STING/type I IFN dependent acute lung inflammation/ARDS. The inflammatory response induced by a synthetic non-nucleotide-based diABZI STING agonist, in comparison to the natural cyclic dinucleotide cGAMP, is unknown. A low dose of diABZI (1 µg by endotracheal route for 3 consecutive days) triggered an acute neutrophilic inflammation, disruption of the respiratory barrier, DNA release with NET formation, PANoptosis cell death, and inflammatory cytokines with type I IFN dependent acute lung inflammation. Downstream upregulation of DNA sensors including cGAS, DDX41, IFI204, as well as NLRP3 and AIM2 inflammasomes, suggested a secondary inflammatory response to dsDNA as a danger signal. DNase I treatment, inhibition of NET formation together with an investigation in gene-deficient mice highlighted extracellular DNA and TLR9, but not cGAS, as central to diABZI-induced neutrophilic response. Therefore, activation of acute cell death with DNA release may lead to ARDS which may be modeled by diABZI. These results show that airway targeting by STING activator as a therapeutic strategy for infection may enhance lung inflammation with severe ARDS.

Details

Title
STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS)
Author
Messaoud-Nacer Yasmine 1 ; Culerier Elodie 2 ; Rose, Stéphanie 2 ; Maillet, Isabelle 2 ; Rouxel Nathalie 3 ; Briault Sylvain 4 ; Ryffel Bernhard 5 ; Quesniaux Valerie F J 2 ; Togbe Dieudonnée 2   VIAFID ORCID Logo 

 CNRS -UMR7355, Orleans Cedex 2, France; University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921) 
 CNRS -UMR7355, Orleans Cedex 2, France (GRID:grid.112485.b); University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921) 
 Artimmune SAS, Orleans, France (GRID:grid.112485.b) 
 University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921); Genetics department, Regional Hospital Orleans (CHRO), Orleans, France (GRID:grid.413932.e) (ISNI:0000 0004 1792 201X) 
 CNRS -UMR7355, Orleans Cedex 2, France (GRID:grid.413932.e); University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921); Artimmune SAS, Orleans, France (GRID:grid.112485.b) 
Publication year
2022
Publication date
Mar 2022
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2643122367
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.